ZTS — Zoetis Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1555280 ·
Last close
$83.48
Market Cap
$33.92B
52W High
$130.12
52W Low
$68.31
ADV30
4,441,200
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 2,468,000,000 1,795,000,000 999,000,000 691,000,000 15,077,000,000 1,473,000,000 11,929,000,000
Mar 2026 2,262,000,000 1,621,000,000 822,000,000 601,000,000 15,154,000,000 1,940,000,000 11,921,000,000
Dec 2025 2,387,000,000 1,675,000,000 826,000,000 603,000,000 15,467,000,000 2,310,000,000 12,136,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,773,000,000
Investing CF
$-815,000,000
Financing CF
$-2,866,000,000
CapEx
$-495,000,000
Dividends Paid
$-886,000,000
Buybacks
$-3,750,000,000
EPS Diluted TTM
$5.88
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$15,246,000,000
Inventory
$2,536,000,000
Receivables
$1,692,000,000
ST Investments
$200,000,000
EBIT TTM
$3,356,000,000
Pretax Income TTM
$3,114,000,000
Interest Exp TTM
$242,000,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,493,999,616
EBITDA
$4,032,000,000
Free Cash Flow
$2,053,124,992
Enterprise Value
$39,985,500,160
Total Cash
$1,532,999,936
Total Debt
$9,256,999,936
Shares Out
406,316,147
Trailing EPS
$5.88
Book Value
$8.11
ROE
57.6%
ROA
14.9%
Div Yield
2.67%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 9,467,000,000 3,597,000,000 2,673,000,000 15,467,000,000 12,136,000,000 3,331,000,000 2,904,000,000
Dec 2024 9,256,000,000 3,392,000,000 2,486,000,000 14,237,000,000 9,467,000,000 4,770,000,000 2,953,000,000
Dec 2023 8,544,000,000 3,069,000,000 2,344,000,000 14,286,000,000 9,295,000,000 4,997,000,000 2,353,000,000
Dec 2022 8,080,000,000 2,928,000,000 2,114,000,000 14,925,000,000 10,522,000,000 4,405,000,000 1,912,000,000

TTM Snapshot

Revenues TTM
$9,517,000,000
NetIncome TTM
$2,616,000,000
OpCashFlow TTM
—
Assets (Latest)
$15,077,000,000
Forward EPS
$6.40

Max Pain — expiry 2026-12-18

max pain strike: $75.00 · spot: $85.57 · call oi: 9,114 · put oi: 32,652
Expected Move to 2026-12-18: ±$6.49 (7.58%) — implied range $79.08 – $92.06 · ATM straddle on $85.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GMAB GENMAB A/S $31.95B $51.96 —
RPRX Royalty Pharma plc $30.58B $68.68 —
ROIV Roivant Sciences Ltd. $28.05B $38.71 —
INSM INSMED Inc $26.73B $121.86 —
ONC BeOne Medicines Ltd. $43.55B $413.26 —

News headlines (Yahoo Finance, 1h cache)

ETFs Are Net Sellers of Zoetis (ZTS) on Monday
2026-11-18 11:03 · Yahoo
GSK vs. Zoetis: Which Dividend Stock Pays You More in 10 Years?
2026-11-13 17:39 · Yahoo
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
2026-11-12 13:48 · Yahoo
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
2026-11-11 12:30 · Yahoo
What Are Wall Street Analysts' Target Price for Zoetis Stock?
2026-11-11 10:52 · Yahoo
Should You Buy Zoetis Stock At This Price?
2026-11-11 00:27 · Yahoo
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
2026-11-10 12:30 · Yahoo
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
2026-11-10 09:41 · Yahoo
ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook
2026-11-09 14:00 · Yahoo
What Zoetis (ZTS) Said on Its Q3 Earnings Call
2026-11-08 22:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.